Teenagers Are Choosing Wegovy Over the Operating Room
Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | July 30, 2026
—
The way American teenagers are getting treated for obesity has changed more in the last three years than in the previous three decades. A new national study, published in JAMA Pediatrics on July 20, shows that GLP-1 medications have nearly swallowed pediatric obesity treatment whole — and bariatric surgery has fallen off a cliff.
Researchers at UT Southwestern analyzed records for 204,148 adolescents and young adults (ages 13 to 25) treated for obesity between May 2022 and January 2026 using Epic Cosmos, a database drawn from more than 300 million patient records.
The numbers:
- Exclusive GLP-1 use: 88.2% → 96.1%
- Bariatric surgery: 11.6% → 3.7%
- Combined surgery + GLP-1: stuck at 0.2% in both periods
The shift lines up with the FDA’s December 2022 approval of semaglutide for adolescents 12 and older. Once a pill or weekly shot became an option, the OR stopped being the default for most families.
Lead author Dr. Sarah Messiah called it “an inflection point in pediatric obesity treatment.” She’s not wrong. We’re watching an entire treatment paradigm reshuffle in real time.
What Nobody’s Figured Out Yet
Here’s the uncomfortable part: nobody knows the optimal sequencing. Should a teenager start with medication and add surgery if results plateau? Start with surgery and use medication to maintain? Try both at once? Real-world data shows combination therapy is essentially nonexistent (0.2%), but the study’s authors — including senior author Dr. Sarah Barlow — flagged this as the next urgent question for pediatric obesity medicine.
The other open question is duration. Most adults come off GLP-1s within two years and regain most of the weight. For a 14-year-old starting semaglutide today, we’re talking about a lifetime of medication — and we don’t have 30-year safety data on that yet.
Why Colorado Is Watching This Closely
Children’s Hospital Colorado, just up I-25 in Aurora, runs the region’s only dedicated pediatric weight management program. University of Colorado School of Medicine faculty there — including Drs. Megan Kelsey and Jaime Moore — recently published clinical guidance on prescribing these drugs to adolescents. Colorado pediatricians are actively walking families through exactly these decisions right now.
For parents of teens in Denver, Greenwood Village, or anywhere along the Front Range, the practical takeaway is this: GLP-1s work in adolescents the same way they work in adults — meaningful weight loss, real side effects, no clear endpoint. Surgery is now the rare exception rather than the rule. The conversation has shifted, but the long-term playbook is still being written.
—
Source: Messiah SE et al. Trends in GLP-1 Receptor Agonist Use and Metabolic and Bariatric Surgery in U.S. Adolescents and Young Adults. JAMA Pediatrics. Published online July 20, 2026.